Postoperative nausea and vomiting (PONV) affects approximately 30% of surgical patients and remains one of the most common complications following anesthesia. PONV can prolong recovery, increase the risk of complications, delay discharge, and reduce patient satisfaction. Preventing PONV is an important part of perioperative care. One of the most commonly used medications for postoperative nausea and vomiting prophylaxis is ondansetron, a 5-HT3 receptor antagonist. However, there is ongoing debate about the optimal timing of ondansetron administration to minimize the risk of PONV.

A randomized controlled trial published in 2008 compared patients who received 4 mg of ondansetron before anesthesia induction with those who received ondansetron 30 minutes before the end of surgery. The study, which included 372 patients, found no difference in PONV incidence in the immediate postoperative period but did find a significant reduction in late PONV (2–24 hours postoperatively) when ondansetron was administered near the end of surgery.

However, a more recent randomized controlled trial published in 2023 found no significant difference in PONV incidence when ondansetron was administered one hour before induction versus 30 minutes before the end of surgery. It is worth noting that this study had a smaller sample size of 121 patients, but it reflects the broader mixed findings in the literature regarding ondansetron timing. This raises an important clinical question: how important is the timing of ondansetron administration for prophylaxis compared to other factors that influence PONV risk?

Ondansetron has a half-life of approximately 3–6 hours. For shorter procedures, administration before induction may provide adequate coverage throughout the perioperative period. For longer procedures, administration closer to the end of surgery may be more effective in preventing postoperative symptoms, particularly later in recovery. While pharmacokinetics suggest that timing could matter, PONV is a multifactorial condition, and timing is only one contributing factor.

Several patient-specific risk factors are known to significantly increase the likelihood of PONV, including female sex, non-smoking status, history of PONV or motion sickness, and postoperative opioid use. These risk factors are incorporated into the Apfel risk score, which is commonly used to guide prophylaxis decisions.

Current anesthesia guidelines recommend a risk-stratified approach to PONV prevention. Patients at higher risk are typically treated with multimodal prophylaxis using medications that act on different receptor pathways. A common regimen includes dexamethasone administered at induction of anesthesia and ondansetron administered near the end of surgery. This combination targets multiple emetogenic pathways and has been shown to be more effective than single-agent prophylaxis.

Ondansetron remains a cornerstone of PONV prophylaxis, but evidence on the ideal timing of administration is mixed. Earlier studies suggested that dosing near the end of surgery may reduce late PONV, whereas more recent data have not demonstrated a meaningful difference in overall incidence. Given the multifactorial nature of PONV, the most effective approach is risk-stratified, multimodal prophylaxis rather than reliance on ondansetron timing alone.

References

1) Tang J, Wang B, White PF, et al. The effect of timing of ondansetron administration on its efficacy for preventing postoperative nausea and vomiting. Anesth Analg. 2008;106(2):463-468. https://pubmed.ncbi.nlm.nih.gov/18450232/

2) Zhang Y, Wang X, Chen Z, Li M. Effect of timing of ondansetron administration on postoperative nausea and vomiting: A randomized controlled trial. BMC Anesthesiol. 2023;23:214. https://pubmed.ncbi.nlm.nih.gov/37466110/

3) Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology. 1999;91(3):693-700. https://pubmed.ncbi.nlm.nih.gov/10485781/

4) Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411-448. https://pubmed.ncbi.nlm.nih.gov/32467512/